Buch, Englisch, 356 Seiten, Format (B × H): 152 mm x 229 mm, Gewicht: 730 g
Buch, Englisch, 356 Seiten, Format (B × H): 152 mm x 229 mm, Gewicht: 730 g
ISBN: 978-0-12-824485-2
Verlag: William Andrew Publishing
Zielgruppe
Basic scientists, clinicians, students and postdoctoral fellows with an interest in cancer biology and oncology, plus related areas in genetics, immunology, pharmacology, cell biology, and molecular biology.
Fachgebiete
- Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Klinische und Innere Medizin Immunologie
- Naturwissenschaften Biowissenschaften Zellbiologie
- Naturwissenschaften Biowissenschaften Virologie
- Naturwissenschaften Biowissenschaften Biowissenschaften Genetik und Genomik (nichtmedizinisch)
Weitere Infos & Material
1. A brief history of RAS and the RAS Initiative
Frank McCormick
2. Not all RAS mutations are equal: A detailed review of the functional diversity of RAS hot spot mutations
Rachel A. Burge and G. Aaron Hobbs
3. Drug targeting opportunities en route to Ras nanoclusters
Karolina Pavic, Rohan Chippalkatti, and Daniel Abankwa
4. Targeting the ERK mitogen-activated protein kinase cascade for the treatment of KRAS-mutant pancreatic cancer
J. Nathaniel Diehl, Priya S. Hibshman, Irem Ozkan-Dagliyan, Craig M. Goodwin, Sarah V. Howard, Adrienne D. Cox, and Channing J. Der
5. Pan-RAS inhibitors: Hitting multiple RAS isozymes with one stone
Alexander B. Coley, Antonio Ward, Adam B. Keeton, Xi Chen, Yulia Maxuitenko, Aishwarya Prakash, Feng Li, Jeremy B. Foote, Donald J. Buchsbaum, and Gary A. Piazza
6. Targeting RAS oncogenesis with SOS1 inhibitors
Roman Christian Hillig and Benjamin Bader
7. Inhibition of SHP2 as an approach to block RAS-driven cancers
Yu-Ting Chou and Trever G. Bivona
8. Targeting the "undruggable� RAS with biologics
Michael Whaby, Imran Khan, and John P. O'Bryan
9. Unraveling and targeting RAS-driven metabolic signaling for therapeutic gain
Jonathan M. DeLiberty, Ryan Robb, Claire E. Gates, and Kirsten L. Bryant
10. The RASopathies: Biology, genetics and therapeutic options
Jody Fromm Longo and Steven L. Carroll